1FEIDMAN D L, ZELENKOFSKE S, DINBOECK M, et al. Use of renin inhibitors, alone or in combination with other agents, for treatment of cardiovascular and other diseases: WO, 2005/089731 [P]. 2005 - 09 - 29.
2WEBB R L. Drug combination for treatment of cardiovascular disorders: WO, 2007/056324 [P]. 2007 - 05 - 18.
3WEBB R L. Combination chemotherapy containing renin inhibitors and antiobesity agents for the treatment of dyslipidemia and obesity.. WO, 2007/048027 [ P]. 2007 - 04 - 26.
4LINDSAY K B, SKRYDSTRUP T. Formal total synthesis of the potent renin inhibitor aliskiren: application of a smi2-prorooted acyl-like radical coupling[J]. J Org Chem, 2006, 71 (13) : 4766 - 4777.
5DONG H, ZHANG Z L, HUANG J H, et al. Practical synthesis of an orally active renin inhibitor aliskiren [J]. Tetrahedron Lett, 2005, 46(37) :6337 - 6340.
同被引文献41
1European public assessment report (EPAR) rasilez summary for the public[EB/OL].2009-04.http://www.emea.europa.eu/humandocs/Humans/EPAR/rasilez/rasilez.htm.
2MHRA Drug Safety Update.Aliskiren (Rasilez):risk of angioedema and renal dysfunction[EB/OL].2009,2(10):2-3.http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON046451.
3EMEA.European Medicines Agency recommends new contraindication and warning for Rasilez and other aliskiren medicines[EB/OL].2009-2-19.http://www.emea.europa.eu/pdfs/human/press/pr/8952309en.pdf.
4Aliskiren (Tekturma)for hypertension[J].Med Left Drugs Ther,2007,49(1258), 29-31.
5Van Tassell BW,Munger MA.Aliskiren for renin inhibition:a new class of antihypertensives[J]. Ann Pharmacother, 2007,41 (5): 456-464.
7Liu DZ,Wang RH, Nie by modified extraction-gravimetry sensor[J].Journal of Pharmaceut LH,et aI.Determination of dipyridamole with a surface acorstic wave resonator cal and Biomedical Anatysis,1996,.
8] EMEA.Europoan Medicines Agency recommends new contraindication and warning for ~asilez and other aliskiren medicines[EB/OL].2009-2-19.
9Satyanarayana R M;Thirumalai R S;Eswuraiah S.Process for the preparation of(2S,4S,5S,7S)-N-(2-carbarny-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-(4-methoxy-3-(3-methoxypropoxy)phenzyl)-octanamide hemifumarate and its intermediates,2011.
10Mayumi M;Kazuhisa S;Yasushi M.Method for producing optically active (4E)-5-chloro-2-isopropyl-4-pentenonic acid or basic amino acid salt,2007.
